

PRESS RELEASE

Development of New Canine Cancer Therapy backed by Eurostars.



Eurostars the transnational programme that has a 1.4 billion euro budget to support research-performing SME's to develop innovative products, process and services for competitive advantage is backing the development of a new antivasular drug to fight cancer in dogs.

Ecrins Therapeutics the French based pharmaceutical company lead by Dr Andrei Popov has teamed up with Swiss based Animal Oncology and Imaging Centre's Dr Barbara Kaser-Hotz and UK's leading private Small Animal Cancer Treatment Centre VRCC. Dr Susan North of VRCC is pictured to the left of Dr Popov and Dr Kaser-Hotz at the recent formal signing of the CADAC consortium agreement in Lyon.

Ecrins have already invested over 2 million euro's in this antivasular drug development and the Eurostar contribution will add a further 1.6 million euro's (£1.4m) towards testing and developing this new and exciting treatment option to come to the market in a few years time. The CADAC project starts in April 2015 and is scheduled to run for 3 years.

Ecrins Therapeutics, AOIC and VRCC came 19th out of 323 Eurostars eligible applications, a long and complex procedure expertly managed by F-Iniciativas's Lionel Arnaud. They are all now looking forward to working together and playing an important contribution to the improvement of cancer treatment in dogs in the not too distant future.

www.ecrins-therapeutics.com

www.aoicenter.ch

<http://www.vrcc.co.uk>

31st March 2015.

For further information contact: info@aoicenter.ch

